View Item 

Show simple item record

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism
dc.contributor.authorShi, Jian
dc.contributor.authorXiao, Jingcheng
dc.contributor.authorWang, Xinwen
dc.contributor.authorJung, Sun Min
dc.contributor.authorBleske, Barry E.
dc.contributor.authorMarkowitz, John S.
dc.contributor.authorPatrick, Kennerly S.
dc.contributor.authorZhu, Hao-Jie
dc.date.accessioned2022-04-08T18:01:57Z
dc.date.available2023-05-08 14:01:55en
dc.date.available2022-04-08T18:01:57Z
dc.date.issued2022-04
dc.identifier.citationShi, Jian; Xiao, Jingcheng; Wang, Xinwen; Jung, Sun Min; Bleske, Barry E.; Markowitz, John S.; Patrick, Kennerly S.; Zhu, Hao-Jie (2022). "Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism." Clinical Pharmacology & Therapeutics (4): 878-885.
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttps://hdl.handle.net/2027.42/171977
dc.publisherWiley Periodicals, Inc.
dc.titlePlasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171977/1/cpt2486.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171977/2/cpt2486-sup-0003-TableS4.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171977/3/cpt2486_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171977/4/cpt2486-sup-0002-TableS3.pdf
dc.identifier.doi10.1002/cpt.2486
dc.identifier.sourceClinical Pharmacology & Therapeutics
dc.identifier.citedreferenceHer, L.H. et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br. J. Clin. Pharmacol. ( 2021 ). https://doi.org/10.1111/bcp.14888.
dc.identifier.citedreferenceLian, J.H., Nelson, R. & Lehner, R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell 9, 178 – 195 ( 2018 ).
dc.identifier.citedreferenceKristensen, K.E. et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin. Pharmacol. Ther. 96, 713 – 722 ( 2014 ).
dc.identifier.citedreferenceQian, Y., Gilliland, T.K. & Markowitz, J.S. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem. Biol. Interact. 316, 108914 ( 2020 ).
dc.identifier.citedreferenceQian, Y. & Markowitz, J.S. Natural products as modulators of CES1 activity. Drug Metab. Dispos. 48, 993–1007 ( 2020 ).
dc.identifier.citedreferenceWang, X., Rida, N., Shi, J., Wu, A.H., Bleske, B.E. & Zhu, H.-J. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab. Dispos. 45, 1149 – 1155 ( 2017 ).
dc.identifier.citedreferenceZhu, H.-J., Wang, X., Gawronski, B.E., Brinda, B.J., Angiolillo, D.J. & Markowitz, J.S. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J. Pharmacol. Exp. Ther. 344, 665 – 672 ( 2013 ).
dc.identifier.citedreferenceTarkiainen, E.K. et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin. Pharmacol. Ther. 97, 650 – 658 ( 2015 ).
dc.identifier.citedreferenceLewis, J.P. et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet. Genomics 23, 1 – 8 ( 2013 ).
dc.identifier.citedreferenceTarkiainen, E.K. et al. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br. J. Clin. Pharmacol. 80, 1131 – 1138 ( 2015 ).
dc.identifier.citedreferenceWang, X. et al. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Transl. Sci. 14, 1380 – 1389 ( 2021 ).
dc.identifier.citedreferenceIgnjatovic, V. et al. Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data. J. Proteome Res. 18, 4085 – 4097 ( 2019 ).
dc.identifier.citedreferenceZhong, W., Edfors, F., Gummesson, A., Bergström, G., Fagerberg, L. & Uhlén, M. Next generation plasma proteome profiling to monitor health and disease. Nat. Commun. 12, 2493 ( 2021 ).
dc.identifier.citedreferenceImai, T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab. Pharmacokinet. 21, 173 – 185 ( 2006 ).
dc.identifier.citedreferenceRodrigues, D. & Rowland, A. From endogenous compounds as biomarkers to plasma-derived nanovesicles as liquid biopsy; has the golden age of translational pharmacokinetics-absorption, distribution, metabolism, excretion-drug–drug interaction science finally arrived? Clin. Pharmacol. Ther. 105, 1407 – 1420 ( 2019 ).
dc.identifier.citedreferenceAchour, B. et al. Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clin. Pharmacol. Ther. 109, 222 – 232 ( 2021 ).
dc.identifier.citedreferenceCouto, N. et al. Quantitative proteomics of clinically relevant drug-metabolizing enzymes and drug transporters and their intercorrelations in the human small intestine. Drug Metab. Dispos. 48, 245 – 254 ( 2020 ).
dc.identifier.citedreferenceOhtsuki, S. et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83 – 92 ( 2012 ).
dc.identifier.citedreferenceSanford, J.C. et al. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenet. Genomics 26, 197 – 207 ( 2016 ).
dc.identifier.citedreferenceRowland, A. et al. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure. Br. J. Clin. Pharmacol. 85, 216 – 226 ( 2019 ).
dc.identifier.citedreferenceRodrigues, A.D. et al. Exploring the use of serum-derived small extracellular vesicles as liquid biopsy to study the induction of hepatic cytochromes p450 and organic anion transporting polypeptides. Clin. Pharmacol. Ther. 110, 248 – 258 ( 2021 ).
dc.identifier.citedreferenceLi, J., Liu, S., Shi, J., Wang, X., Xue, Y. & Zhu, H.-J. Tissue-specific proteomics analysis of anti-COVID-19 nucleoside and nucleotide prodrug-activating enzymes provides insights into the optimization of prodrug design and pharmacotherapy strategy. ACS Pharmacol. Translat. Sci. 4, 870 – 887 ( 2021 ).
dc.identifier.citedreferenceHer, L. & Zhu, H.-J. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab. Dispos. 48, 230 – 244 ( 2020 ).
dc.identifier.citedreferenceLauschke, V.M., Milani, L. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. AAPS J. 20, 4 ( 2017 ).
dc.identifier.citedreferenceRelling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464 – 467 ( 2011 ).
dc.identifier.citedreferenceGeyer, P.E., Holdt, L.M., Teupser, D. & Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol. 13, 942 ( 2017 ).
dc.identifier.citedreferenceSchwenk, J.M. et al. The human plasma proteome draft of 2017: building on the human plasma PeptideAtlas from mass spectrometry and complementary assays. J. Proteome Res. 16, 4299 – 4310 ( 2017 ).
dc.identifier.citedreferenceRobbi, M. & Beaufay, H. The COOH terminus of several liver carboxylesterases targets these enzymes to the lumen of the endoplasmic reticulum. J. Biol. Chem. 266, 20498 – 20503 ( 1991 ).
dc.identifier.citedreferenceYan, B., Yang, D., Bullock, P. & Parkinson, A. Rat serum carboxylesterase. Cloning, expression, regulation, and evidence of secretion from liver. J. Biol. Chem. 270, 19128 – 19134 ( 1995 ).
dc.identifier.citedreferenceBahar, F.G., Ohura, K., Ogihara, T. & Imai, T. Species difference of esterase expression and hydrolase activity in plasma. J. Pharm. Sci. 101, 3979 – 3988 ( 2012 ).
dc.identifier.citedreferenceWang, X., Liang, Y., Liu, L., Shi, J. & Zhu, H.-J. Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI). Rapid Commun. Mass Spectrom. 30, 553 – 561 ( 2016 ).
dc.identifier.citedreferenceShi, J. et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem. Pharmacol. 119, 76 – 84 ( 2016 ).
dc.identifier.citedreferenceShi, J., Wang, X., Nguyen, J., Wu, A.H., Bleske, B.E. & Zhu, H.-J. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab. Dispos. 44, 554 – 559 ( 2016 ).
dc.identifier.citedreferenceSun, Z. et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J. Pharmacol. Exp. Ther. 310, 469 – 476 ( 2004 ).
dc.identifier.citedreferenceZhu, H.-J. et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82, 1241 – 1248 ( 2008 ).
dc.identifier.citedreferenceNemoda, Z., Angyal, N., Tarnok, Z., Gadoros, J. & Sasvari-Szekely, M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 57, 731 – 733 ( 2009 ).
dc.identifier.citedreferenceZhu, H.-J. et al. Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers. J. Clin. Psychopharmacol. 37, 419 – 428 ( 2017 ).
dc.identifier.citedreferenceShi, J., Wang, X., Lyu, L., Jiang, H. & Zhu, H.-J. Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. Drug Metab. Pharmacokinet. 33, 133 – 140 ( 2018 ).
dc.identifier.citedreferenceShi, J. et al. Determining allele-specific protein expression (ASPE) using a novel quantitative concatamer based proteomics method. J. Proteome Res. 17, 3606 – 3612 ( 2018 ).
dc.identifier.citedreferenceShi, J. et al. FRACPRED-2D-PRM: a fraction prediction algorithm-assisted 2D liquid chromatography-based parallel reaction monitoring-mass spectrometry approach for measuring low-abundance proteins in human plasma. Proteomics 20, 2000175 ( 2020 ).
dc.identifier.citedreferenceWang, X., He, B., Shi, J., Li, Q. & Zhu, H.-J. Comparative proteomics analysis of human liver microsomes and S9 fractions. Drug Metab. Dispos. 48, 31 – 40 ( 2020 ).
dc.identifier.citedreferenceThe Human Protein Atlas. The liver-specific proteome < https://www.proteinatlas.org/humanproteome/tissue/liver#the_liver_specific_proteome > ( 2021 ).
dc.identifier.citedreferenceThe Human Protein Atlas, Liver Enriched Gene Expression < https://www.proteinatlas.org/search/tissue_category_rna:liver;Tissue+enriched+AND+sort_by:tissue+specific+score > ( 2021 ).
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt2486.pdf
Size:
591.2KB
Format:
PDF
View/Open
Name:
cpt2486-sup-0003-TableS4.pdf
Size:
229.6KB
Format:
PDF
View/Open
Name:
cpt2486_am.pdf
Size:
365.2KB
Format:
PDF
View/Open
Name:
cpt2486-sup-0002-TableS3.pdf
Size:
209.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.